# Sar444656 (kt-474) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sar444656-kt-474

> Sar444656 (kt-474), sponsored by Sanofi (SNY): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | sar444656 (kt-474) |
| Codes | SAR444656, KT-474 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Atopic Dermatitis](https://sec-api.dev/indications/atopic-dermatitis), [Hidradenitis Suppurativa](https://sec-api.dev/indications/hidradenitis-suppurativa) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### October 9, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Hidradenitis Suppurativa.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06028230 (A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-09 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06028230

### October 23, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06058156 (Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-23 (ACTUAL); Lead Sponsor Sanofi; Results First Posted 2026-11-03." https://clinicaltrials.gov/study/NCT06058156

## Same indication

- [Cibinqo (abrocitinib)](https://sec-api.dev/pdufa/abrocitinib) (PFE)
- [ATI-045](https://sec-api.dev/pdufa/ati-045) (ACRS)
- [Avtx-009 regimen 1](https://sec-api.dev/pdufa/avtx-009-regimen-1) (AVTX)
- [Barzolvolimab](https://sec-api.dev/pdufa/barzolvolimab) (CLDX)
- [BRINSUPRI® (brensocatib)](https://sec-api.dev/pdufa/brensocatib) (INSM)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)
- [GHZ339](https://sec-api.dev/pdufa/ghz339) (NVS)
- [GIA632](https://sec-api.dev/pdufa/gia632) (NVS)
- [KT-621](https://sec-api.dev/pdufa/kt-621) (KYMR)
- [Lebrikizumab](https://sec-api.dev/pdufa/lebrikizumab) (LLY)
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab) (ABBV)
- [Olatorepatide](https://sec-api.dev/pdufa/olatorepatide) (REGN)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [PF-08049820](https://sec-api.dev/pdufa/pf-08049820) (PFE)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)
- [Litfulo (ritlecitinib tosylate)](https://sec-api.dev/pdufa/ritlecitinib) (PFE)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Roflumilast cream 0.3%](https://sec-api.dev/pdufa/roflumilast-cream-0-3) (ARQT)
- [JAKAFI (ruxolitinib)](https://sec-api.dev/pdufa/ruxolitinib) (INCY)
- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream) (INCY)
- [SAR445399](https://sec-api.dev/pdufa/sar445399) (SNY)
- [Sonelokimab](https://sec-api.dev/pdufa/sonelokimab) (MLTX)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [Tulisokibart](https://sec-api.dev/pdufa/tulisokibart) (MRK)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [Zasocitinib (dose a)](https://sec-api.dev/pdufa/zasocitinib-dose-a) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sar444656-kt-474.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Sar444656 (kt-474) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sar444656-kt-474

```bibtex
@misc{secapidev_pdufa_sar444656_kt_474_20261116,
  title        = {Sar444656 (kt-474) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sar444656-kt-474}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sar444656_kt_474_20261116","title":"Sar444656 (kt-474) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sar444656-kt-474","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
